Lixte Biotechnology’s LB-100 Reported to Convert Immunologically Unresponsive (“Cold”) Tumors to Immunologically Responsive (“Hot”) Tumors
05 Gennaio 2022 - 2:30PM
Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT), a
clinical-stage drug discovery company developing pharmacologically
active drugs for use in cancer treatment, announced today that in
preclinical studies its lead clinical compound, LB-100, a protein
phosphatase (PP2A) inhibitor, was found to increase the
responsiveness of diverse cancers to immunotherapy. In Nature
Communications (15 Dec 2021), lead author Yu-Ting Yen and
colleagues at the China Medical University and Hospital, Taichung,
Taiwan reported that treatment with LB-100 is associated with new
antigen production, tumor infiltration of cytotoxic T cells, and
enhanced responsiveness to immune checkpoint blockade in mouse
models of colorectal, triple-negative breast, and pancreatic
cancer. The authors state that “these data indicate that PP2A
inhibition can be used to change the intrinsic and extrinsic
factors of tumors to improve the success rate of anti-cancer
immunotherapy.”
Lixte’s founder and CEO, John S. Kovach M.D,
commented that “recent advances in therapy with immune checkpoint
inhibitors have been a true breakthrough in the development of more
effective and less toxic treatment for many cancers. Unfortunately,
most cancer patients do not respond to immunotherapy. There are
widespread efforts to find pharmacologic and/or immunologic ways to
turn unresponsive (‘cold’) tumors into responsive (‘hot’) tumors.
Cancers with a molecular abnormality termed
microsatellite-instability (MSI) stemming from a defect in a DNA
repair enzyme are generally ‘hot’ tumors, that is, tumors
responsive to immunotherapy. Yen and colleagues now report that
pharmacologic inhibition of PP2A by LB-100 modifies two distinct
molecular pathways resulting in conversion of microsatellite stable
(MSS) tumors into MSI tumors sensitive immune checkpoint blockade
therapy.”
Dr. Kovach concluded: “The results of Yen et al.
raise the possibility that the addition of LB-100 to immunotherapy
may be a simple way to convert ‘cold’ into ‘hot’ tumors, thereby
increasing the percentage of patients responsive to immunotherapy.
Lixte recently initiated a clinical trial in patients with
previously untreated extensive stage small cell lung cancer in
which LB-100 is first added to chemotherapy and an immune
checkpoint blocker and then administered with the immune blocker
alone in the maintenance phase of treatment (NCT04560972). Lixte is
interested in collaborative studies designed to determine whether
LB-100 broadly enhances the benefit of immunotherapy. Immune
checkpoint blockers are now approved for treatment of at least 20
cancer types.”
About Lixte
Biotechnology Holdings, Inc.
Lixte Biotechnology Holdings, Inc. (Nasdaq:
LIXT) is a clinical-stage pharmaceutical company dedicated to
discovering drugs for more effective treatments for many forms of
cancer and other serious common diseases. A major driver of
cancer is defects in the switches that turn the biochemical
pathways in cells on and off. Most cancer research over the past 30
years has focused on the “on” switches because the “off” switches,
especially the master “off” switch protein phosphatase (PP2A), were
believed to cause intolerable toxicity in patients. Lixte has
achieved a breakthrough with its novel, first-in-class lead
clinical compound and PP2A inhibitor, LB-100, by demonstrating that
this compound is readily tolerated in cancer patients at doses
associated with anti-cancer activity. This innovative approach
encourages cancer cells damaged by chemo or other cancer therapies
to continue to replicate before repairing the damage, leading to
more efficient killing of those cells. LB-100 is being tested in
three clinical cancer treatment studies with others in
planning. www.lixte.com
Forward-Looking Statements
This announcement contains certain
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933, and Section 21E of the Securities Exchange
Act of 1934. For example, statements regarding the Company's
financial position, business strategy and other plans and
objectives for future operations, and assumptions and predictions
about future product demand, supply, manufacturing, costs,
marketing and pricing factors are all forward-looking statements.
These statements are generally accompanied by words such as
"intend," anticipate," "believe," "estimate," "potential(ly),"
"continue," "forecast," "predict," "plan," "may," "will," "could,"
"would," "should," "expect" or the negative of such terms or other
comparable terminology. The Company believes that the assumptions
and expectations reflected in such forward-looking statements are
reasonable, based on information available to it on the date
hereof, but the Company cannot provide assurances that these
assumptions and expectations will prove to have been correct or
that the Company will take any action that the Company may
presently be planning. However, these forward-looking statements
are inherently subject to known and unknown risks and
uncertainties. Actual results or experience may differ materially
from those expected or anticipated in the forward-looking
statements. Factors that could cause or contribute to such
differences include, but are not limited to, regulatory policies,
available cash, research results, competition from other similar
businesses, and market and general economic factors. This
discussion should be read in conjunction with the Company's filings
with the United States Securities and Exchange Commission at
sec.gov/edgar.shtml.
Lixte
Contact:info@lixte.comGeneral Phone: (631)
830-7092Investor Phone: (888) 289-5533
Grafico Azioni Lixte Biotechnology (NASDAQ:LIXT)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni Lixte Biotechnology (NASDAQ:LIXT)
Storico
Da Lug 2023 a Lug 2024